These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8422184)

  • 1. [Development of antimetabolites, II].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):19-26. PubMed ID: 8422184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New analogues of methotrexate].
    Yoshimura A
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2133-9. PubMed ID: 1444480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent development of antitumor antimetabolites in Japan--cytosine arabinoside analogues].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1997 May; 24(7):761-70. PubMed ID: 9170512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New antitumor antimetabolites--gemcitabine and DMDC].
    Matsui K; Fukuoka M
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2127-32. PubMed ID: 1332622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate analogues. 19. Replacement of the glutamate side chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity.
    Rosowsky A; Forsch RA; Freisheim JH; Moran RG; Wick M
    J Med Chem; 1984 May; 27(5):600-4. PubMed ID: 6546949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifolates: the next generation.
    Fleming GF; Schilsky RL
    Semin Oncol; 1992 Dec; 19(6):707-19. PubMed ID: 1462168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
    Schornagel JH; Verweij J; de Mulder PH; Cognetti F; Vermorken JB; Cappelaere P; Armand JP; Wildiers J; de Graeff A; Clavel M
    J Clin Oncol; 1995 Jul; 13(7):1649-55. PubMed ID: 7602354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential selection during therapy in vivo by edatrexate compared to methotrexate of resistant L1210 cell variants with decreased folylpolyglutamate synthetase activity.
    Rumberger BG; Schmid FA; Otter GM; Sirotnak FM
    Cancer Commun; 1990; 2(9):305-10. PubMed ID: 2206778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of classical non-polyglutamylatable antifolates that inhibit dihydrofolate reductase.
    Abraham A; Nair MG; McGuire JJ; Galivan J; Kisliuk RL; Vishnuvajjala BR
    Adv Exp Med Biol; 1993; 338():663-6. PubMed ID: 8304202
    [No Abstract]   [Full Text] [Related]  

  • 10. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
    Yamagami K; Fujii A; Arita M; Okumoto T; Sakata S; Matsuda A; Ueda T; Sasaki T
    Cancer Res; 1991 May; 51(9):2319-23. PubMed ID: 2015596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
    Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
    Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antifolates in clinical development.
    Takimoto CH; Allegra CJ
    Oncology (Williston Park); 1995 Jul; 9(7):649-56, 659 DISC 660, 662, 665. PubMed ID: 8924375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice.
    Kuehl M; Brixner DI; Broom AD; Avery TL; Blakley RL
    Cancer Res; 1988 Mar; 48(6):1481-8. PubMed ID: 2449950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
    Cadman E; Eiferman F
    J Clin Invest; 1979 Sep; 64(3):788-97. PubMed ID: 288743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edatrexate, an antifolate with antitumor activity: a review.
    Grant SC; Kris MG; Young CW; Sirotnak FM
    Cancer Invest; 1993; 11(1):36-45. PubMed ID: 8422595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of edatrexate in patients with metastatic colorectal cancer.
    Clamon GH; Riggs CE; Dreicer R; Hohl RJ
    Invest New Drugs; 1996; 13(4):359-61. PubMed ID: 8824357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.
    Jordheim LP; Cros E; Gouy MH; Galmarini CM; Peyrottes S; Mackey J; Perigaud C; Dumontet C
    Clin Cancer Res; 2004 Aug; 10(16):5614-21. PubMed ID: 15328204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
    Hashida M; Kojima T; Muranishi S; Sezaki H
    Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.